Literature DB >> 12090344

Comparison of T1c versus T2 prostate cancers in Japanese patients undergoing radical prostatectomy.

Y Furuya1, S Ohta, N Sato, T Kotake, M Masai.   

Abstract

In order to examine the characteristics of patients with nonpalpable prostate cancer (T1c cancer) in Japan, patients treated with radical prostatectomy were compared with those with palpable (T2) cancer. Prostate-specific antigen (PSA) level in patients with T2b disease was significantly higher than those with T1c and T2a tumors. At the time of radical prostatectomy, 78%, 71% and 31% of patients with T1c, T2a, and T2b, respectively, had organ-confined disease. When insignificant cancer was defined as volume 0.5 ml or less and Gleason score less than 5, only 2 of 34 (5.9%) with clinical T1c disease were clinically insignificant. T1c cancers were clinically significant and clinicopathological features of Tlc tumors were similar to T2a tumors. PSA measurement could detect potentially curable prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12090344     DOI: 10.1023/a:1014461105701

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  14 in total

1.  Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients.

Authors:  T A Stamey; J N Kabalin; J E McNeal; I M Johnstone; F Freiha; E A Redwine; N Yang
Journal:  J Urol       Date:  1989-05       Impact factor: 7.450

2.  Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging.

Authors:  D F Gleason; G T Mellinger
Journal:  J Urol       Date:  1974-01       Impact factor: 7.450

Review 3.  Prospective evaluation of men with stage T1C adenocarcinoma of the prostate.

Authors:  H B Carter; J Sauvageot; P C Walsh; J I Epstein
Journal:  J Urol       Date:  1997-06       Impact factor: 7.450

4.  Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies.

Authors:  Y Goto; M Ohori; A Arakawa; M W Kattan; T M Wheeler; P T Scardino
Journal:  J Urol       Date:  1996-09       Impact factor: 7.450

5.  Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy.

Authors:  R Ghavamian; M L Blute; E J Bergstralh; J Slezak; H Zincke
Journal:  Urology       Date:  1999-07       Impact factor: 2.649

6.  PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors.

Authors:  J E Oesterling; V J Suman; H Zincke; D G Bostwick
Journal:  Urol Clin North Am       Date:  1993-11       Impact factor: 2.241

7.  Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis.

Authors:  S E Lerner; T M Seay; M L Blute; E J Bergstralh; D Barrett; H Zincke
Journal:  J Urol       Date:  1996-03       Impact factor: 7.450

8.  Preoperative predictors for organ-confined disease in Japanese patients with stage T1c prostate cancer.

Authors:  O Ogawa; S Egawa; Y Arai; K Tobisu; O Yoshida; T Kato
Journal:  Int J Urol       Date:  1998-09       Impact factor: 3.369

9.  Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men.

Authors:  J E Oesterling; Y Kumamoto; T Tsukamoto; C J Girman; H A Guess; N Masumori; S J Jacobsen; M M Lieber
Journal:  Br J Urol       Date:  1995-03

10.  Characteristics of prostate cancer detected in the American Cancer Society-National Prostate Cancer Detection Project.

Authors:  C Mettlin; G P Murphy; F Lee; P J Littrup; A Chesley; R Babaian; R Badalament; R A Kane; F K Mostofi
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450

View more
  1 in total

1.  An Analytical Study of Prostate-Specific Antigen Dynamics.

Authors:  Ernesto P Esteban; Giovanni Deliz; Jaileen Rivera-Rodriguez; Stephanie M Laureano
Journal:  Comput Math Methods Med       Date:  2016-11-13       Impact factor: 2.238

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.